Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Wada, Satoshi ^a,c   Jackson, Christopher M ^a   Yoshimura, Kiyoshi ^a,d   Yen, Hung Rong ^a   Getnet, Derese ^a   Harris, Timothy J ^a   Goldberg, Monica V ^a   Bruno, Tullia C ^a   Grosso, Joseph F ^a,e   Durham, Nicholas ^a   Netto, George J ^a,b   Pardoll, Drew M ^a   Drake, Charles G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c SAITAMA RED CROSS HOSPITAL   (Japan)

^d YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

CTLA 4; Immunotherapy; Lymphocyte; Prostate cancer; Treg

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EFFECTOR CELL; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CTLA-4 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84875689651     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-89     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512. 10.1056/NEJMoa040720, 15470213.
3. Seruga B, Tannock IF. Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer. J Clin Oncol 2011, 29(27):3686-3694. 10.1200/JCO.2010.34.3996, 21844499.
4. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011, 29:3651-3658.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005. 10.1056/NEJMoa1014618, 3471149, 21612468.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012, 367:1187-1197. 10.1056/NEJMoa1207506, 22894553.
7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. 10.1056/NEJMoa1001294, 20818862.
8. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010, 10:580-593. 10.1038/nri2817, 3082366, 20651745.
9. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113:975-984. 10.1002/cncr.23669, 18646045.
10. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004, 64:6337-6343. 10.1158/0008-5472.CAN-04-0757, 15342423.
11. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366. 10.1084/jem.190.3.355, 2195583, 10430624.
12. Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs 2011, 71:1093-1104. 10.2165/11594010-000000000-00000, 21668044.
13. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA 2010, 107:1524-1528. 10.1073/pnas.0910341107, 2824392, 20080649.
14. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008, 112:1175-1183. 10.1182/blood-2007-11-125435, 2515138, 18523152.
15. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
16. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547. 10.1016/1074-7613(95)90125-6, 7584144.
17. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999, 96:15074-15079. 10.1073/pnas.96.26.15074, 24775, 10611340.
18. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60:2444-2448.
19. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005, 7:239-249. 10.1016/j.ccr.2005.01.027, 2846360, 15766662.
20. Getnet D, Maris CH, Hipkiss EL, Grosso JF, Harris TJ, Yen HR, Bruno TC, Wada S, Adler A, Georgantas RW. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol 2009, 182:4675-4685. 10.4049/jimmunol.0803400, 3082355, 19342643.
21. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007, 117:3383-3392. 10.1172/JCI31184, 2000807, 17932562.
22. Mihalyo MA, Hagymasi AT, Slaiby AM, Nevius EE, Adler AJ. Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. Prostate 2007, 67:536-546. 10.1002/pros.20549, 2846359, 17221844.
23. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009, 69:4309-4318. 10.1158/0008-5472.CAN-08-4102, 3084614, 19435909.
24. Morgan DJ, Liblau R, Scott B, Fleck S, McDevitt HO, Sarvetnick N, Lo D, Sherman LA. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol 1996, 157:978-983.
25. Kirberg J, Baron A, Jakob S, Rolink A, Karjalainen K, von Boehmer H. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med 1994, 180:25-34. 10.1084/jem.180.1.25, 2191558, 8006585.
26. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998, 95:1178-1183. 10.1073/pnas.95.3.1178, 18712, 9448305.
27. Berglund P, Finzi D, Bennink JR, Yewdell JW. Viral alteration of cellular translational machinery increases defective ribosomal products. J Virol 2007, 81:7220-7229. 10.1128/JVI.00137-07, 1933321, 17459927.
28. Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999, 10:1983-1991. 10.1089/10430349950017347, 10466632.
29. Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky HI, Pardoll DM, Fuchs EJ. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2003, 101:1645-1652. 10.1182/blood-2002-07-2233, 12406877.
30. Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF, Harris TJ, Getnet D, Whartenby KA. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007, 110:186-192. 10.1182/blood-2006-12-062422, 1896112, 17392506.
31. Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001, 249:99-110. 10.1016/S0022-1759(00)00329-X, 11226468.
32. Huss WJ, Maddison LA, Greenberg NM. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 2001, 11:245-260. 10.1006/scbi.2001.0373, 11407949.
33. Yoshimura K, Laird LS, Chia CY, Meckel KF, Slansky JE, Thompson JM, Jain A, Pardoll DM, Schulick RD. Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res 2007, 67:10058-10066. 10.1158/0008-5472.CAN-07-0573, 17942940.
34. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003, 55:219-237. 10.1002/pros.10215, 12692788.
35. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007, 117:1167-1174. 10.1172/JCI31202, 1857250, 17476346.
36. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
37. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006, 116:1935-1945. 10.1172/JCI27745, 1479425, 16778987.
38. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010, 59:663-674. 10.1007/s00262-009-0782-8, 2832083, 19890632.
39. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:501-508. 10.1016/S1470-2045(12)70006-2, 22326924.
40. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:509-517. 10.1016/S1470-2045(12)70007-4, 22326922.
41. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011, 17:4101-4109. 10.1158/1078-0432.CCR-11-0407, 3117971, 21558401.
42. May KF, Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate Cancer Immunotherapy. Clin Cancer Res 2011, 17:5233-5238. 10.1158/1078-0432.CCR-10-3402, 3263933, 21700764.
43. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010, 16:2781-2791. 10.1158/1078-0432.CCR-09-3243, 20460483.
44. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009, 7:35. 10.1186/1479-5876-7-35, 2697137, 19457253.
45. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010, 10:248-256. 10.1038/nri2742, 3242804, 20336152.
46. Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother 2011, 60:197-206. 10.1007/s00262-010-0927-9, 3202216, 20976449.
47. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011, 33:369-383. 10.1007/s00281-011-0245-0, 21611872.